Skip to main content
HOB BIOTECH GROUP CORP.,LTD. logo

HOB BIOTECH GROUP CORP.,LTD. — Investor Relations & Filings

Ticker · 688656 ISIN · CNE100004C37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 630 across all filing types
Latest filing 2023-12-21 AGM Information
Country CN China
Listing Shanghai Stock Exchange 688656

About HOB BIOTECH GROUP CORP.,LTD.

http://en.hob-biotech.com/

HOB Biotech Group Corp., Ltd. specializes in the development, manufacture, and distribution of in vitro diagnostic (IVD) products, with a primary focus on allergy and autoimmune disease testing. The company provides a comprehensive range of diagnostic solutions, including enzyme-linked immunosorbent assays (ELISA), line immunoassays, and advanced chemiluminescence immunoassay (CLIA) systems. Its product portfolio covers hundreds of allergens and a wide array of autoimmune markers, catering to clinical laboratories and healthcare providers. HOB Biotech is recognized for its proprietary technology platforms that enable high-throughput, automated testing, improving diagnostic efficiency and accuracy. The company's commitment to research and development supports the continuous expansion of its diagnostic menu to address evolving clinical needs in immunology and hypersensitivity.

Recent filings

Filing Released Lang Actions
江苏浩欧博生物医药股份有限公司2023年第三次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled "2023 年第三次临时股东大会会议资料" which translates to "2023 Third Extraordinary General Meeting (EGM) Meeting Materials". It contains detailed meeting instructions, agenda, and proposals for the shareholders' meeting, including amendments to the company's articles of association and governance rules. The content is focused on the materials prepared for the shareholders to review and discuss at the meeting, including voting procedures and legal compliance. This matches the description of AGM Information (AGM-R), which includes presentations and materials shared during general meetings. Although it is an extraordinary meeting (临时股东大会), the category AGM-R covers such shareholder meeting materials. The document is lengthy (15,000 characters) and contains substantive meeting materials, not just an announcement or voting results. Therefore, the correct classification is AGM Information (AGM-R).
2023-12-21 Chinese
江苏浩欧博生物医药股份有限公司监事会议事规则
Governance Information Classification · 95% confidence The document is titled as the 'Rules of Procedure for the Supervisory Board Meeting' of Jiangsu Haoyoubo Biopharmaceutical Co., Ltd. It details the governance structure, composition, powers, meeting procedures, and responsibilities of the supervisory board. There is no financial data, no mention of financial results, no shareholder voting results, no executive changes, no legal proceedings, no capital updates, and no regulatory filings. The content is focused on internal governance rules and procedures, which aligns with governance information about the company's internal rules and board structure. The document length is 3666 characters, which is relatively short but contains substantive governance content rather than an announcement or a brief note. Therefore, the most appropriate classification is Governance Information (CGR).
2023-12-11 Chinese
江苏浩欧博生物医药股份有限公司独立董事工作细则
Governance Information Classification · 100% confidence The document is titled '独立董事工作细则' which translates to 'Independent Director Work Rules' and contains detailed provisions about the governance structure, duties, nomination, election, and responsibilities of independent directors in the company. It references relevant laws, regulations, and governance codes, and outlines internal governance practices. There is no financial data, earnings information, or audit results. The content is focused on governance practices and internal rules related to board members. Therefore, this document fits the category of Governance Information (CGR). The document length is sufficient and it is not a brief announcement or certification, so it is not RNS or RPA.
2023-12-11 Chinese
江苏浩欧博生物医药股份有限公司关联交易制度
Governance Information Classification · 95% confidence The document is titled '关联交易制度' which translates to 'Related Party Transaction System' or 'Related Party Transaction Policy' for Jiangsu Haoyoubo Biopharmaceutical Co., Ltd. It details the principles, definitions, decision-making procedures, and governance related to related party transactions within the company. The content is regulatory and governance-focused, outlining compliance with laws, listing rules, and company articles. It is not a financial report, earnings release, or announcement of voting results. It is a governance document describing internal rules and procedures for related party transactions. Therefore, it fits best under Governance Information (CGR). The document length (5755 characters) and detailed procedural content support this classification with high confidence.
2023-12-11 Chinese
江苏浩欧博生物医药股份有限公司募集资金管理制度
Governance Information Classification · 95% confidence The document is titled '募集资金管理制度' which translates to 'Fundraising Capital Management System' and details the internal rules and procedures for the management, storage, and use of funds raised by the company. It references regulatory requirements, internal controls, and supervisory responsibilities related to fundraising capital. The content is a policy or governance document rather than a financial report, earnings release, or announcement. It does not contain financial statements or results but rather governance and compliance rules regarding capital management. Therefore, it fits best under Governance Information (CGR). The document length is over 6000 characters, indicating it is a full policy document, not a brief announcement or certification.
2023-12-11 Chinese
江苏浩欧博生物医药股份有限公司章程
Governance Information Classification · 100% confidence The document is titled as the Articles of Association (章程) of 江苏浩欧博生物医药股份有限公司 dated December 2023. It contains detailed provisions about the company's organization, shareholder rights, board structure, share issuance, shareholder meetings, voting procedures, and other governance matters. It references relevant laws such as the Company Law and Securities Law of China. The content is a comprehensive governance document outlining the internal rules and regulations of the company rather than a financial report, announcement, or meeting minutes. Therefore, it fits the category of Governance Information (CGR). The document length is substantial and contains the full text of the governance charter, not just an announcement or summary.
2023-12-11 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.